Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use
US11524009B2 · kind B2 · utility
0Cited by
3References
34Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 30, 2018 |
| Grant date | Dec 13, 2022 |
| Priority date | — |
| Expiry date | Oct 30, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2300/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides pharmaceutical combinations comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors. Also provided are methods of treating cancer comprising administering a therapeutically effective amount of at least one spliceosome modulator and a therapeutically effective amount of at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.